GSK earns FDA approval for Jideytro
GSK secured FDA approval for Jideytro (zidesamtinib), its first lung cancer medicine, for ROS1-positive NSCLC after prior ROS1 inhibitor treatment. The approval, based on ARROS-1 trial data showing a 44% objective response rate, came ahead of the September 18 target date. Jideytro is part of GSK’s $10.6 billion acquisition of Nuvalent, fueling its push to expand its oncology portfolio. The drug is a next-generation ROS1 inhibitor designed to be selective and to cross the blood-brain barrier to address brain metastases and resistance mutations. It will compete with existing ROS1 therapies like Xalkori and Rozlytrek and faces sales uncertainty in a competitive market. GSK's leadership positions this approval as a milestone in rebuilding its cancer drug business under CEO Luke Miels, with further Nuvalent assets progressing, including neladalkib.
Where do you stand?
How it spread
Claim check
What each side asserts, disputes — or leaves out entirely.
Where do you land?
Whose framing of this story rings truest to you?
How each side headlines it
Left· 0 sources
No left coverage yet — a bubble gap.
Right· 1 source
“GSK wins FDA nod for Jideytro lung cancer drug (GSK:NYSE)”
